Randall Schatzman - Alder BioPharmaceutica Co-Founder, CEO and President and Director

CEO

Dr. Randall C. Schatzman. Ph.D., is President, Chief Executive Officer, Director of the Company. Dr. Schatzman served as Senior Vice President of Discovery Research at Celltech RD, Inc., a whollyowned subsidiary of Celltech Group plc, a biopharmaceutical company, where he led a group of scientists responsible for much of the therapeutic antibody pipeline for Celltech. From 1995 to 1999, Dr. Schatzman served as Director of Gene Discovery at Mercator Genetics Inc., a genomics company. From 1987 to 1995, Dr. Schatzman served as Section Leader at Roche Bioscience, previously Syntex Corporationration, a subsidiary of Roche Holdings Ltd., a biotechnology company, where he helped found the Cancer and Developmental Biology Institute since 2004.
Age 61
Tenure 20 years
Professional MarksPh.D
Phone425 205-2900
Webwww.alderbio.com
Schatzman holds a Ph.D. in Molecular Pharmacology from Emory University and a B.S. in Biochemistry from Purdue University.

Randall Schatzman Latest Insider Activity

Tracking and analyzing the buying and selling activities of Randall Schatzman against Alder BioPharmaceutica stock is an integral part of due diligence when investing in Alder BioPharmaceutica. Randall Schatzman insider activity provides valuable insight into whether Alder BioPharmaceutica is net buyers or sellers over its current business cycle. Note, Alder BioPharmaceutica insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alder BioPharmaceutica'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Alder BioPharmaceutica Management Efficiency

The company has return on total asset (ROA) of (100.8551) % which means that it has lost $100.8551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4193) %, meaning that it created substantial loss on money invested by shareholders. Alder BioPharmaceutica's management efficiency ratios could be used to measure how well Alder BioPharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 193.36 M in liabilities with Debt to Equity (D/E) ratio of 89.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alder BioPharmaceuticals has a current ratio of 8.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alder BioPharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Alder BioPharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alder BioPharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alder to invest in growth at high rates of return. When we think about Alder BioPharmaceutica's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CEO Age

Eric AlexandreOrbit Garant Drilling
N/A
Jeremy ThigpenTransocean
49
Tom KellyAerCap Holdings NV
56
Christopher CzarneckiBroadstone Net LeaseInc
43
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Alder BioPharmaceutica operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 202 people. Alder BioPharmaceuticals (ALDR) is traded on NASDAQ Exchange in USA and employs 202 people.

Management Performance

Alder BioPharmaceuticals Leadership Team

Elected by the shareholders, the Alder BioPharmaceutica's board of directors comprises two types of representatives: Alder BioPharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alder. The board's role is to monitor Alder BioPharmaceutica's management team and ensure that shareholders' interests are well served. Alder BioPharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alder BioPharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Erin Lavelle, COO
Xavier GallotLavallee, Member of the Supervisory Board
Deepa Pakianathan, Independent Director
Bruce Montgomery, Independent Director
Paul Streck, Chief Medical Officer
Anne TrotouxCoppermann, Member of the Supervisory Board
Robert Azelby, President CEO
Christian Viguie, Chairman of the Supervisory Board
Deepika Pakianathan, Independent Director
John Latham, Co-Founder and Chief Scientific Officer
Jeremy Green, Director
Bruno Pavlovsky, Member of the Supervisory Board
Wendy Yarno, Independent Director
Joel Desmaris, Member of the Management Board in Charge of Finance and Investor Relations
Olivier Lambert, Member of the Supervisory Board
Randal Hassler, Senior Vice President Pharmaceutical Operations
Paul Carter, Director
Stephen Dow, Independent Chairman of the Board
Randall Schatzman, Co-Founder, CEO and President and Director
Eric Carter, Interim Chief Medical Officer
Nadia Dac, Chief Commercial Officer
Mark Litton, Chief Business Officer, Treasurer and Secretary
Larry Benedict, Sr. VP of Fin.
Carlos Campoy, CFO
Pierre Conte, Member of the Supervisory Board
Pierre Tourrette, Vice Chairman of the Supervisory Board
Heather Preston, Independent Director
Jeffrey Smith, Senior Vice President Translational Medicine
Timothy Whitaker, Chief Medical Officer
James Bucher, Senior Vice President General Counsel
Paul Cleveland, Director
Clay Siegall, Independent Director
Frederic Serre, Chairman of the Management Board
Elisabeth Sandoval, Chief Commercial Officer
Philippe Mattia, Member of the Supervisory Board

Alder Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alder BioPharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Alder BioPharmaceutica

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alder BioPharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alder BioPharmaceutica will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Genuine Parts could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genuine Parts when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genuine Parts - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genuine Parts Co to buy it.
The correlation of Genuine Parts is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genuine Parts moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genuine Parts moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genuine Parts can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Alder BioPharmaceuticals information on this page should be used as a complementary analysis to other Alder BioPharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in Alder Stock

If you are still planning to invest in Alder BioPharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alder BioPharmaceutica's history and understand the potential risks before investing.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges